Sosei Heptares’ Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development under Multi-Program Collaboration with Neurocrine Biosciences
August 04, 2022 19:05 ET
|
Sosei Group Corporation
Neurocrine to conduct placebo-controlled Phase 2 study to investigate NBI-1117568 (formerly HTL-0016878) as a potential new treatment for schizophrenia Clinical development milestone triggers payment...
Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases
August 01, 2022 19:05 ET
|
Sosei Group Corporation
New strategic collaboration leverages Sosei Heptares’ StaR® technology and SBDD platform and AbbVie’s extensive neuroscience expertise Second collaboration with AbbVie follows 2020 agreement focused...
Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate into clinical trials
July 21, 2022 19:05 ET
|
Sosei Group Corporation
TOKYO, Japan and LONDON and CAMBRIDGE, United Kingdom, July 22, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), an international biopharmaceutical company and...
Orion Biotechnology and Peptilogics Enter Strategic Research Collaboration to Enable AI-Driven Drug Discovery Against Undrugged GPCR Target
July 12, 2022 11:22 ET
|
Orion Biotechnology Canada Ltd.
Ottawa, Canada & Pittsburgh, USA, July 12, 2022 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd, a drug discovery company targeting previously undruggable G Protein-Coupled Receptors (GPCRs),...
Sosei Heptares Webinar Presentation for Q2 FY2022 Financial Results
July 11, 2022 05:30 ET
|
Sosei Group Corporation
TOKYO, Japan and CAMBRIDGE, United Kingdom, July 11, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) will announce its earnings results and present operational highlights...
Sosei Heptares Expands UK R&D Operations to Second Site within Granta Park, Cambridge
May 26, 2022 02:30 ET
|
Sosei Group Corporation
TOKYO, Japan and CAMBRIDGE, United Kingdom, May 26, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), world leader in G protein-coupled receptor (GPCR) focused...
Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR Targets for Drug Discovery
May 17, 2022 02:30 ET
|
Sosei Group Corporation
Collaboration is part of Sosei Heptares’ Target Identification and Validation (TIV) strategy to leverage multiple sophisticated technologies that drive creation of new drug discovery programs in key...
Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2022
May 13, 2022 02:30 ET
|
Sosei Group Corporation
TOKYO, Japan and CAMBRIDGE, United Kingdom, May 13, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its...
ORION BIOTECHNOLOGY PRESENTING NEW DATA ON ITS LATEST BEST-IN-CLASS GPCR DRUG CANDIDATE
May 10, 2022 13:03 ET
|
Orion Biotechnology Canada Ltd.
Ottawa, Canada, May 10, 2022 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd, a drug discovery and development company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs),...
Sosei Heptares to Embed Agile Operating Model and Enhance its Translational Medicine Capabilities through Strategic Collaboration with Weatherden
April 26, 2022 02:30 ET
|
Sosei Group Corporation
Key focus on enabling prioritization and rapid progression of pipeline programs through to clinical proof-of-concept, a key milestone for value creationSosei Heptares will use the collaboration to...